OBJECTIVES: Despite the introduction of new target drugs to treat pulmonary metastatic renal cell carcinoma (mRCC), complete surgical resection still generates significantly longer survival. We analysed the survival outcome for patients with pulmonary mRCC after extended laser metastasectomy with up to 110 metastases and systematic lymphadenectomy to assess the utility and value of laser resection in the respective patient groups even with high number of metastases.
INTRODUCTION
Renal cell carcinoma (RCC) remains an important cause of cancer death in Europe, accounting for 3% of all cancers and 27 000 deaths in 2006. Thirty percent of RCC patients still present with metastases at the time of diagnosis, and an additional 30% of patients initially judged to have localized tumours later develop metastases [1, 2] .
Under the treatment of mRCC with interferon, tyrosinekinase inhibitors (TKIs) and other new target therapies [mammalian target of rapamycin (mTOR)-inhibitors], the majority of patients experienced partial response and only 3% of patients had a complete response with a median overall survival of 25 months [3] [4] [5] .
Over the last two decades, numerous studies have confirmed the ability of complete lung metastasectomy to produce significantly higher 5-year survival rates of 20-60%, in contrast to 3% for unresectable disease [6] [7] [8] [9] .
In 80% of these reports, stapler resection comprised the dominant surgical technique, whereas laser resection was used in 15% of European thoracic centres [8] . In these study, 20-40% of patients received lobectomies and typically had an average of 2 resected metastases. Reports on patients with 6-9 metastases, on the other hand, are infrequent. Since most of the studies excluded patients with multiple or even bilateral multiple metastases, judging this extent of tumour spread to constitute systemic disease or to be unsuitable for the preferred stapler resection technique, the utility and benefit of metastasectomy in patients suffering from a higher number of lung metastases has still not been defined.
In 2006, we reported on 328 patients after complete pulmonary metastasectomy using the 1318 nm Neodym-doped YttriumAluminium-Granat (Nd:YAG) laser [10] , showing that this technique facilitated the complete resection of a significantly higher number of metastases from a variety of primary tumours compared with conventional stapler resection in other reports, while achieving similar long-term survival rates. After another 8 years of experience and additional application of a new 1318 nm diode laser since 2007 which has reduced the time needed for resection to just one-third compared with the Nd:YAG laser equipment, we are now able to provide our results after laser resection of pulmonary metastases from single tumour entities.
We therefore collected data on 237 consecutive patients whose mainly multiple pulmonary metastases from mRCC were resected by the tissue-saving 1318 nm laser with a curative intent, including a sub-group of 73 patients with between 10 and 110 metastases, to evaluate the survival outcome of this surgical approach.
MATERIALS (PATIENTS) AND METHODS

Patient characteristics and surgical technique
Between January 1996 and March 2012, 237 consecutive patients (150 men, 87 women, mean age: 64) underwent laser resection of pulmonary metastases from exclusively clear cell RCC with curative intent. Within the same period, 68 referred patients were excluded from surgical therapy due to local RCC recurrence (n = 12), unresectable pulmonary (n = 14) and extrathoracic (n = 21) metastases, multilevel and bulky N2 lymph node involvement (n = 15) and functional inoperability (n = 6). These patients merely received palliative systemic (TKI) therapy.
Patients with multiple, synchronous or bilateral lung metastases were eligible for this study with no exclusion for the number of metastases and mediastinal lymph node involvement up to onelevel N2, provided that complete technical and functional resectability was assumed.
Thirty-five of 237 patients had synchronous pulmonary metastases at the time of RCC diagnosis and curative resection. The remaining 202 patients developed metachronous metastases.
Preoperative evaluations are the same as for routine thoracic operations and include history, physical examination, chest and upper abdominal computer tomography (CT) scan, bronchoscopy and pulmonary function tests. We do not regularly perform positron emission tomography (PET)-scan in patients with pulmonary metastases from RCC. Regional assessment of the tumour situation in the abdomen/retroperitoneum and pelvic to rule out local recurrence or extrapulmonary metastases is done by CT or magnetic resonance tomography (MRT). PET scan cannot detect brain metastases. If there is reasonable suspicion of brain metastases, a MRT is done. From our point of view, PET does not add much diagnostic information. PET scan cannot detect small (<1 cm) pulmonary metastases and the data of the literature are sparse. In a report from 2011, PET-CT not otherwise than CT alone could detect all malignant pulmonary nodules that were found intraoperatively by palpation of the lung [11] .
All pulmonary laser resections are performed via an anteroaxillary muscle-sparing approach. If the disease is bilateral, we begin with the side considered more difficult, and the procedures are performed 6 weeks apart, or even longer if permitted by the progression of the disease. In cases with similar spread to both lungs, we begin with resection of the right lung, so this larger lung will be available for one-lung ventilation during the second operation. After initial laser metastasectomy, patients are followed up in our outpatient clinic by CT scan and respiratory lung function test after 3 months, afterwards every 6 months. New growing and progressive nodules are assessed as recurrent metastases and rethoracotomy is scheduled provided that functional and anatomic resectability is present.
In 1996, we started with a 1318 nm Nd:YAG laser which was limited in its power output to 40 W and was described earlier [10, 12, 13] . Since 2007, a new developed high-power pure diode laser was used which can deliver the 1318 nm wavelength at up to 150 W of power due to its 10-fold improvement in energy efficiency. Changes in the construction and coating of its bare fibres have made it possible to operate with the fibres directly contacting the lung tissue, which makes surgery much easier to perform. During surgery, complete atelectasis of the lung is mandatory to allow the surgeon to palpate nodules down to 1 mm and to get an optimal interaction between this 1318 nm wavelength and the targeted tissue. All palpable nodules are resected with a safety margin of 2 mm and sampled for histological examination. Through the heat effect of the laser on the lung tissue, the safety margin extends another 5 mm into the remaining tissue [10] . At the end of this procedure, all laser resection caverns are sutured with approximating running suture.
In cases in which CT scan indicated enlarged hilar or mediastinal lymph nodes, an endoscopic ultrasound (EUS/EBUS)-guided biopsy of the enlarged lymph nodes is done. Patients with histologically confirmed unilateral single-level hilar/mediastinal lymph node involvement are scheduled for metastasectomy with radical systematic lymph node dissection, whereas all patients without pathological findings in CT scan and/or EUS/EBUS-guided biopsy receive systematic lymph node sampling with intraoperative smear cytology of sampled lymph nodes.
In case of intraoperative evidence of lymph node involvement, a radical lymph node dissection is performed as well. Lymph node sampling and radical dissection-if necessary-included the same positions as for standard dissection in lung cancer: paratracheal (2, 4), sub-/para-aortic (5, 6), subcarinal (7), paraoesophageal (8); pulmonary ligament (9) and hilar/interlobar (10, 11) .
A postoperative histological finding of either lymphangiosis carcinomatosa or metastatic growth extending beyond the capsule of the resected lymph node is classified as R1; incompletely removed (multilevel N2, bulky) lymph node metastasis is judged as R2.
Data collection and statistics
Patients with pulmonary metastases of RCC were entered prospectively into a computerized registry. The study was approved by the ethical review committee at the University Hospital Dresden and informed consent was obtained from each patient. The followup data were obtained retrospectively by clinical examination and CT scan in our outpatient clinic, by letter or telephone.
Survival after lung metastasectomy was estimated by the Kaplan-Meier method and survival distributions were compared by use of log-rank statistics.
Multivariate analysis of following prognostic factors was performed using the Cox multivariate proportional hazard model: resection status, number of metastases, lymph node involvement, localization (uni-vs bilateral), synchronous/metachronous metastases, disease-free interval after RCC-resection (DFI-PUL) and year of operation, to account for changes in diagnostic technology. A P-value of <0.05 was considered statistically significant.
RESULTS
The follow-up after initial pulmonary resection ranged from 2 to 198 months with a mean of 46 months, and was complete for all 237 patients who underwent a total of 406 thoracotomies (136 unilateral, 202 bilateral sequential and 68 rethoracotomies).
There was no perioperative and 30-day mortality. Postoperative resection-specific complications included prolonged air leakage in 6 and intrathoracic/intraparenchymal bleeding in 3 further cases. All these complications were successfully overcome conservatively without necessitating a rethoracotomy. Ninety-two percent of operated patients underwent a lung function test 6 months after thoracotomy in our outpatient clinic and all of these showed 80-100% of the preoperative respiratory performance parameters.
Altogether, 3567 palpable pulmonary nodules (mean 15/patient) were removed, of which 2996 nodules (84%) were histologically confirmed metastases of RCC (mean 13/patient), whereas 16% (n = 571) of all resected nodules proved to be benign and were excluded from further calculations.
Of the 237 patients, 208 (88%) had a complete resection (R0 N0, or R0N1/2) with a mean of 13 metastases resected (range: 1-110). The reasons for incomplete resections in 29 patients (R1/n = 3, R2/n = 26) were unexpected miliary spread (n = 8), unresectable/multilevel mediastinal lymph node metastases or lymphangiosis (n = 18) and pleural dissemination (n = 3).
Neither neoadjuvant therapy prior to pulmonary metastasectomy nor adjuvant therapy was given after initial curative resection (n = 208). Patients with incomplete (R1/R2) resection (n = 29) received ( palliative) systemic TKI therapy.
Five-year survival and median overall survival for R0-patients was 54% and 69 months, respectively (Table 1) , compared with 7% and 19 months in those with incomplete resections (Fig. 1) . In multivariate Cox regression, complete resection was the strongest prognostic factor (Table 2, P < 0.0001).
For this R0 group, types of resection are listed in Table 1 . Additional lobectomies or segmentectomies were necessary in cases of very centrally located metastases with infiltration of vascular and/or bronchial structures.
Eighty-three patients with R0-resections (40%) remained recurrence-free ( pulmonary/extrapulmonary) during the followup after a mean of 11 resected metastases (range: 1-84), and achieved 5-year and 10-year survival rates of 76 and 60%, respectively.
Of the 208 R0-patients, 102 (49%) developed pulmonary or pulmonary and extrapulmonary metastatic recurrence (64 unilaterally and 38 bilaterally) after a median interval of 60 months (1-113 months). Among these 102 patients, 43 (42%) had limited recurrence to the lungs (along with resectable extrapulmonary recurrence in 10 cases), and each of these 43 patients subsequently underwent up to 3 rethoracotomies, provided that functional and anatomical operability was present. Thus, complete resection (R0) was achieved again in 41 (95%) of these 43 cases (32 with exclusively pulmonary recurrence, and 9 with pulmonary and resectable extrapulmonary) followed by a median overall survival time of 113 months, or 5-year and 10-year survival rates of 74 and 43%, respectively. These results are significantly better than the median overall survival of 39 months, or 5-year and 10-year survival rates of 27 and 12%, respectively, shown by the 61 patients with either irresectable recurrence (n = 59; 32 pulmonary, 27 pulmonary and extrapulmonary) or R1/R2 resection after rethoracotomy (n = 2), all of whom received palliative systemic TKI therapy (P < 0.00001; Fig. 2 ).
Twenty-three of 208 patients with R0-resections developed exclusive extrapulmonal recurrence (Table 1) .
Only 42 patients (20%) had solitary metastases, 63 (30%) had 2-5 metastases, 30 (14%) had 6-9 metastases, 60 (29%) had 10-29, and 13 (6%) had 30-110 metastases removed. Five-year overall survival for patients with 1, 2-5, 6-9, 10-29 or 30-110 metastases resected was 61.5, 59, 60, 43 and 40%, respectively (P = 0.0332, Fig. 3) .
The 208 R0 patients included 107 (51%) with unilateral metastases with a mean of 6 metastases removed and 101 (49%) who received two-stage surgery for a mean of 20 bilateral metastases. The difference in the number of metastases in the two groups was highly significant (P < 0.00001, Wilcoxon test). There was no significant difference in overall survival between the two sub-groups (log-rank P = 0.619, 5-year survival 56.1 vs 52.2%).
In 52 of 237 patients (22%) with pre-or intraoperative histologically confirmed unilateral single-level hilar/mediastinal lymph node involvement, a systematic radical lymph node dissection was carried out.
In the remaining 185 patients (78%), a systematic hilar/mediastinal lymph node sampling was performed. In 8 of these patients, micro-metastases (<2 mm; no infiltration of the capsule) were histologically confirmed only postoperative in sampled lymph nodes and were assessed as R0-resection, a further rethoracotomy with radical lymph node dissection was not performed.
Thus, in total, 60 of 237 patients (25%) had histologically confirmed lymph node involvement. In 42 (70%) of these patients, a complete resection of both their pulmonary metastases and involved lymph nodes was achieved (R0N1/n = 19; R0N2/n = 23). The remaining 18 patients had incomplete resections of tumour infiltrated lymph nodes due to multilevel N2 involvement or lymphangiosis, which represented the most important risk factor for incomplete resections, and received palliative systemic therapy. The 42 patients with positive lymph nodes (R0N1/R0N2) had a 5-year survival of 44% (median: 55 months) compared with 57% (median: 83 months) for the 166 patients (R0N0) without lymph node involvement (log-rank P = 0.117; Fig. 4) . Likewise, there was no statistical difference between N1 and N2 disease.
Twenty-nine of 208 patients (R0) had synchronous pulmonary metastases at the time of RCC diagnosis. The remaining 179 patients developed metachronous metastases. The 5-year survival The bold values are significant in multivariate analysis. HR: hazard ratio; CI: confidence interval; RCC: renal cell carcinoma; DFI-PUL: disease-free interval after primary tumour resection. of patients with metachronous metastases was 58% (median: 68 months) compared with 34% and 39 months of the patients with synchronous metastases (P = 0.042). Sixty-three of 179 patients with metachronous R0-resected pulmonary metastases had a DFI-PUL after RCC-resection of less than 36 months with a 5-year survival of 58.6% (median survival: 62.4 months). There was no significant difference when compared with 116 patients with a DFI-PUL ≥36 months (62.8%, 64.8 months (P = 0. 22) When considered separately in univariate analysis, completeness of resection (R0 vs R1/R2), number of metastases and synchronous versus metachronous metastases were significant prognostic variables for survival. Age, gender, ECOG-status, primary RCC pT-status, size of lung metastases, lymph node involvement, localization (uni vs bilateral) and DFI-PUL were not significant.
Multivariate Cox regression analysis revealed only the completeness of resection (P < 0.0001) and number of metastases (P = 0.0029) as significant prognostic factors for survival, while correcting for influence of the year of operation (Table 2) .
DISCUSSION
While TKIs have helped significantly to improve survival in patients with mRCC from 9 to 19 months, it is also apparent that their value as neo-or adjuvant treatments in combination with surgery is limited, given that they induce complete remission in only 2-4% of patients, while fully 50% progress under therapy [4, 5, [14] [15] [16] [17] 24] . In contrast, during the same period several studies confirmed the benefits achievable by complete lung metastasectomy [7] [8] [9] [18] [19] [20] [21] [22] [23] , even in patients with multiple sites of disease [18] .
In 2006, we published our results on 328 patients after complete metastasectomy using the 1318 nm Nd:YAG laser [10] , showing that this technique facilitated the complete resection of a significantly higher number of metastases compared with conventional stapler resection in other reports, while achieving similar long-term survival rates [6, 7, [18] [19] [20] [21] [22] [23] .
In the present study, we analysed laser metastasectomy of pulmonary metastases from RCC according to the general eligibility criteria in our hospital. Patients with R0-resection (n = 208, mean of 13 resected metastases per patient) had a 5-year and median overall survival of 54% and 69 months, respectively, compared with 7% and 19 months in those with incomplete resections. In multivariate analysis, completeness of resection was the strongest prognostic factor (P < 0.0001), which is in accordance with previous reports [6] [7] [8] [9] .
In previously published studies, the mean numbers of mRCC resected ranged from 2 to 5 [6] [7] [8] [9] [19] [20] [21] [22] [23] . In contrast, in our 237 patients we resected a mean of 13 metastases, with a R0-rate of 88%. Despite the much greater number of metastases removed, our R0-rates and 5-year survival (54%) still rank in the upper range of the previously cited studies. Eighty-three of the 208 patients (40%) with R0 resection of an average of 11 metastases remained recurrence free without adjuvant treatment, and achieved 5-year and 10-year survival rates of 76 and 60%, respectively.
In another sub-group of 41 patients for whom secondary complete resection was achieved after two or three rethoracotomies for recurrent (new growing) metastases, comparable long-term survival was achieved. This demonstrates again the importance of renewed surgery and complete resection in case of recurrence.
While previous studies have been unanimous in showing the benefit of complete surgical removal of multiple metastases, we show for the first time that this benefit holds even for patients with a significantly higher number of metastases, and that extensive pulmonary disease still differs prognostically from systemic disease (oligometastases) of mRCC.
However, complete resection is the strongest prognostic factor, no matter which resection technique is deployed in the end. Laser resection in itself is not a prognostic factor; we could not draw such a conclusion since we had no control group with other resection techniques. The point is that only laser resection allows complete removal of multiple (up to 110) and centrally-located metastases in a tissue-saving way. Our results show that even though the average number of complete resected metastases was much higher than those from all other reports in the literature, we achieved similar survival rates. Stapler resection of 40 metastases would mutilate the lung without the chance of rethoracotomy.
Many authors have sought to create or evaluate prognostic scores for lung metastasectomy, and many have placed similar emphasis on the number of metastases and the ability to achieve R0 resection. In fact, a significantly poorer outcome has been reported even between a solitary metastasis and two metastases [6] . In contrast, we observed similar outcomes for patients after R0 resection of a single metastasis, 2-5 metastases and 6-9 metastases, with 5-year survival rates being 61, 59 and 60%, respectively (log-rank P = 0.903). Overall survival showed a significant decrease for the sub-groups of 60 and 13 patients who received laser resections of 10-29 and 30-110 metastases, for whom 5-year survival decreased to 43 and 40%, respectively (log-rank P = 0.0078 comparing the groups with <10 and ≥10 metastases).
In the literature, one cannot find studies that analyse the results after resection of such high number of pulmonary metastases. Consequently, there have been no sub-group analyses with such high number of completely removed metastases so far. The results of our sub-group analysis were-unsurprisingly-the same as in previous studies, that is to say: even if complete resection was achieved, patients with high number of metastases (≥10) did worse than patients with solitary or only two to nine metastases.
One could argue that modern CT scans currently can detect more nodules than 15 years ago and that decision-making for resection, extent of resection and overall survival might be different nowadays.
To assess this effect, another Cox regression model on the R0 patients was performed where the time of diagnosis was taken into account. On this set, time of first diagnosis alone is not a significant variable (P = 0.17), and in a Cox model jointly showing first diagnosis and number of metastases together, first diagnosis was also insignificant (P = 0.49), but the number of metastases was highly significant (P = 0.00017). In our data, such an effect was not seen, and there was no significant impact of time of first diagnosis on survival.
In the present study, 3567 palpable pulmonary nodules were removed altogether (intraoperative situation), of which 2996 nodules (84%) were histologically confirmed metastases of RCC (situation after histology). We did not count the nodules on CT and compared this number with the palpable numbers intraoperatively for every patient since it is common and generally approved through the literature that intraoperative assessment of the lung detects 20-30% more nodules than seen on CT scan.
Hence, the crucial point is not the number of nodules on CT scan but the actual number of palpable and resected metastases. The decision for resection is not solely made by assessment of the number of nodules on CT scan. The location of nodules and thereby the technical feasibility of resection are more important. Survival analysis is based on the actual number of resected and histologically proven metastases, not on the numbers seen on CT scan.
Our data revealed that extensive lymph node involvement was the source of most incomplete resections. The role played by lymph node infiltration in determining the outcome of lung metastasectomy of mRCC remains poorly defined, and discussions about its incidence and impact on surgical indications have just started [8, 9, 19, 23] . Analogous to Pfannschmidt et al. [20] and Murthy et al. [22] , we assume that the pulmonary metastases from RCC induce hilar and mediastinal lymph node involvement in a pattern incalculable at the start of the staging process. Therefore, a systematic lymph node sampling should be performed in every patient. In contrast to these authors, however we included the evaluation of the lymph node status in our preoperative/intraoperative work flow (CT scan, bronchoscopy, EBUS; EUS; intraoperative smear cytology). For this study, we have designated patients with unilateral and one-level N1/N2 disease eligible for surgery, and those with bilateral N1 and multilevel N2 ineligible. Using our pre-and intraoperative screening procedure, we detected tumour-positive lymph nodes in 52 of 60 patients with postoperative histologically proven lymph node involvement and thus performed radical lymph node dissection in these 52 patients. However, in 8 patients micro-metastases (<2 mm; no infiltration of the capsule) were histologically confirmed in sampled lymph nodes only postoperative.
In 42 (70%) of these 60 cases, a complete resection of the lymph nodes involved was achieved (R0N1/n = 19; R0N2/n = 23) with a similar distribution between N1 and N2 lymph nodes published by Cerfolio et al. [21] . In these cases, the condition for classification as R0 resection was (i) absence of lymphangiosis carcinomatosa, (ii) no metastatic growth extending beyond the capsule of the resected lymph node and (iii) absence of multilevel N2 or bulky lymph node metastasis. Thus, in these cases, even if a lymph node metastasis was detected, the resection was classified as complete (R0) and no adjuvant therapy was given.
In the remaining 18 patients, multilevel N2 disease (intraoperative) or lymphangiosis prevented complete histologically proven resection. These patients represented 62% of the 29 patients with incomplete resections and received palliative systemic (targeted) therapy after operation. Despite lymphatic involvement, the 42 patients with complete removal of their metastases and their tumour-positive regional lymph nodes had a 5-year overall survival of 44% compared with 57% of the 166 patients without lymph node involvement (log-rank P = 0.117). To explain this observation, we suggest that besides diagnostic information, radical mediastinal/hilar lymphadenectomy increases the therapeutic effect of pulmonary laser metastasectomy and thus the prospect of curative resection and improved survival.
Systematic lymph node sampling and radical dissection in case of pre-or intraoperative evidence of lymph node involvement is therefore essential in patients with mRCC undergoing lung metastasectomy.
Synchronous lung metastases are frequently reported in up to 30% of patients with RCC, and have been associated with a poor prognosis [7, 19] . However, this term has been used inconsistently, often including metastases discovered as much as 11 months after detection of the primary tumour. In our 208 R0 patients, we found that 29 (14%) had lung metastases detected at the time of initial RCC diagnosis. In this group of patients, a 5-year survival of 34% was observed, which was significantly poorer than the 58% 5-year survival of all other 179 R0 patients classified as having metachronous metastases. A further separation of patients with metachronous metastases into those with a disease-free interval of less than 36 months after RCC-resection and those with a longer diseasefree interval showed no significant differences in 5-year survival, with rates of 59 and 63%, respectively (P = 0.22). Thus, while our results confirm once more the poorer prognosis of patients with lung metastases diagnosed synchronously (<1 month) with their primary RCC, we do not recommend excluding such patients from surgery, as they still have a much better chance for long-term survival than is achievable with any other treatment.
It is still unclear whether targeted therapy may play a role following significant surgical cytoreduction in patients with extended spread to the lungs, though Barbastefano et al. [24] recently published that a 90% reduction of tumour burden was associated with prolonged response to systemic therapy. Results from prospectively controlled clinical trials with TKIs or mTOR-inhibitors as neoadjuvant or adjuvant therapy are outstanding [25] .
The impact of targeted therapy has to be evaluated in a next step. Our data so far does not allow for a decisive assessment of the impact of TKIs on survival.
Besides its retrospective design and selection bias due to our inclusion/exclusion criteria, the main limitation of our study is the impossibility to install control groups. Generally, it is difficult to set up a study comprising two groups of TKI-treated patients in which one group is barred from the chance of complete surgical removal of pulmonary metastases. There are mainly ethical considerations. Furthermore, there is little or even no interest from the pharmaceutical industry to implement or back such a study where the impact of complete surgical resection is compared with targeted therapy.
CONCLUSIONS
This study has once again demonstrated that complete resection holds overwhelmingly greater prognostic value for survival than all other frequently reported factors and scores, even in patients with multiple (up to 110) metastases and unilateral one-level N1/N2 disease.
Base on our results, we suggest limiting the eligibility criteria for laser pulmonary metastasectomy of mRCC simply to functional and technical resectability. In our study, these criteria produced a R0 rate of 88%.
Considering the above-average long-term survival after laser metastasectomy, low morbidity and its parenchyma-saving character, we advocate laser resection with systematic lymph node dissection as a standard treatment, even for mRCC patients with multiple and recurrent pulmonary metastases.
